• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Balaxi Share Price

    Balaxi Pharmaceuticals Share PriceBalaxi Pharmaceuticals

    Small Cap Result
    ₹423.45
    7.5 (1.8%)
    As on 10 December, 2023 | 22:27 BSE: NSE: BALAXIISIN: INE618N01014

    Balaxi Pharmaceuticals Performance

    Day Range

    • Low 414.00
    • High 425.00
    ₹ 423.45

    52 Week Range

    • Low 399.95
    • High 670.00
    ₹ 423.45
    • Open Price414.00
    • Previous Close415.95
    • Volume3536

    Start SIP in Balaxi Pharmaceuticals

    Start SIP

    Balaxi Pharmaceuticals Share Price

    • Over 1 Month 0.89%
    • Over 3 Month -10.02%
    • Over 6 Month -19.13%
    • Over 1 Year -26.39%

    Balaxi Pharmaceuticals Key Statistics

    P/E Ratio -40.9
    PEG Ratio 0.3
    Market Cap Cr 433
    Price to Book Ratio 2.4
    EPS 15.9
    Dividend 0
    Relative Strength Index 50.95
    Money Flow Index 52.26
    MACD Signal -2.49
    Average True Range 14.75

    Balaxi Pharmaceuticals Investment Rating

    • Master Rating:

    • Balaxi Pharmaceuticals has an operating revenue of Rs. 287.94 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 17% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Balaxi Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 17253023282621
    Operating Expenses Qtr Cr 16212520252217
    Operating Profit Qtr Cr 1454444
    Depreciation Qtr Cr 0000000
    Interest Qtr Cr 0000000
    Tax Qtr Cr 0111211
    Net Profit Qtr Cr 1344454
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 115104
    Operating Expenses Annual Cr 9184
    Operating Profit Annual in Cr 1717
    Depreciation Cr 10
    Interest Annual Cr 00
    Tax Annual Cr 65
    Net Profit Annual Cr 1615
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr -79
    Cash from Investing Activity Annual Cr -2-7
    Cash from Financing Annual Activity Cr 26-2
    Net Cash Flow Annual Cr 170
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 9258
    Fixed Assets Annual Cr 113
    Total Non Current Assets Annual Cr 3128
    Total Current Assets Annual Cr 9954
    Total Assets Annual Cr 13082
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 9058
    ROE Annual % 1825
    ROCE Annual % 2434
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2220
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 55668187868389
    Operating Expenses Qtr Cr 44576871726978
    Operating Profit Qtr Cr 1191315151411
    Depreciation Qtr Cr 1010000
    Interest Qtr Cr 0000000
    Tax Qtr Cr 1232332
    Net Profit Qtr Cr 14-4188151413
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 339284
    Operating Expenses Annual Cr 280229
    Operating Profit Annual in Cr 5750
    Depreciation Cr 21
    Interest Annual Cr 10
    Tax Annual Cr 117
    Net Profit Annual Cr 4648
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 634
    Cash from Investing Activity Annual Cr -11-28
    Cash from Financing Annual Activity Cr 260
    Net Cash Flow Annual Cr 216
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 183113
    Fixed Assets Annual Cr 196
    Total Non Current Assets Annual Cr 4635
    Total Current Assets Annual Cr 194141
    Total Assets Annual Cr 240176
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 180113
    ROE Annual % 2542
    ROCE Annual % 3148
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1820
    Invest in Balaxi Pharmaceuticals

    Balaxi Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹423.45
    7.5 (1.8%)
    pointer
    • Bullish Moving Average
    • ___
    • 9
    • Bearish Moving Average
    • ___
    • 7
    • 20 Day
    • ₹420.73
    • 50 Day
    • ₹429.92
    • 100 Day
    • ₹450.69
    • 200 Day
    • ₹478.12
    • 20 Day
    • ₹419.17
    • 50 Day
    • ₹427.07
    • 100 Day
    • ₹451.71
    • 200 Day
    • ₹494.91

    Balaxi Pharmaceuticals Resistance and Support

    PIVOT
    ₹420.82
    Resistance
    First Resistance 427.63
    Second Resistance 431.82
    Third Resistance 438.63
    RSI 50.95
    MFI 52.26
    MACD Single Line -2.49
    MACD -1.78
    Support
    First Resistance 416.63
    Second Resistance 409.82
    Third Resistance 405.63

    Balaxi Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 3,536 285,108 80.63
    Week 2,638 183,895 69.71
    1 Month 2,881 192,050 66.65
    6 Month 3,276 214,383 65.45

    Balaxi Pharmaceuticals Result Highlights

    Balaxi Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Balaxi Pharmaceutica is involved in the business activities of Other specialized wholesale. Company’s Total Operating Revenue is Rs. 108.14 Cr. and Equity Capital is Rs. 10.18 Cr. for the Year ended 31/03/2023. Balaxi Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/09/1942 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L25191TG1942PLC121598 and registration number is 000045.
    Market Cap 433
    Sales 95
    Shares in Float 0.30
    No of funds 3
    Yield
    Book Value 4.68
    U/D Vol ratio 0.6
    LTDebt / Equity
    Alpha -0.16
    Beta 0.53

    Balaxi Pharmaceuticals

    Owner NameSep-23Jun-23May-23Mar-23
    Promoters 71.22%71.22%71.22%71.57%
    Mutual Funds
    Insurance Companies
    Foreign Portfolio Investors 18.58%18.58%18.58%18.66%
    Financial Institutions/ Banks 0.03%0.03%0.03%0.03%
    Individual Investors 6.62%6.57%6.48%5.95%
    Others 3.55%3.6%3.69%3.79%

    Balaxi Pharmaceuticals Management

    Name Designation
    Mr. Ashish Maheshwari Managing Director
    Mrs. Minoshi Maheshwari Non Executive Director
    Mrs. Purnima Singh Kamble Independent Director
    Mr. M Srinivas Rao Independent Director
    Mr. Gandhi Gamji Independent Director
    Mr. Kunal M Bhakta Independent Director

    Balaxi Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Balaxi Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-02 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-29 Audited Results & Dividend
    2023-02-01 Quarterly Results
    2022-11-05 Quarterly Results

    Balaxi Pharmaceuticals FAQs

    What is Share Price of Balaxi Pharmaceuticals ?

    Balaxi Pharmaceuticals share price is ₹423 As on 10 December, 2023 | 22:13

    What is the Market Cap of Balaxi Pharmaceuticals ?

    The Market Cap of Balaxi Pharmaceuticals is ₹433.2 Cr As on 10 December, 2023 | 22:13

    What is the P/E ratio of Balaxi Pharmaceuticals ?

    The P/E ratio of Balaxi Pharmaceuticals is -40.9 As on 10 December, 2023 | 22:13

    What is the PB ratio of Balaxi Pharmaceuticals ?

    The PB ratio of Balaxi Pharmaceuticals is 2.4 As on 10 December, 2023 | 22:13

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.